Our top pick for
Cellect Biotechnology Ltd is a biotechnology business based in the US. Cellect Biotechnology shares (APOP) are listed on the NASDAQ and all prices are listed in US Dollars. Cellect Biotechnology employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$9.83 - $35.52|
|50-day moving average||$17.38|
|200-day moving average||$7.39|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.85|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-22)||N/A|
|1 month (2022-05-30)||N/A|
|3 months (2022-03-30)||N/A|
|6 months (2021-12-30)||N/A|
|1 year (2021-07-02)||-100.00%|
|2 years (2020-07-02)||-100.00%|
|3 years (2019-07-03)||-100.00%|
|5 years (2017-06-30)||-100.00%|
|Gross profit TTM||$0|
|Return on assets TTM||-47.79%|
|Return on equity TTM||-120.42%|
|Market capitalisation||$12.9 million|
TTM: trailing 12 months
We're not expecting Cellect Biotechnology to pay a dividend over the next 12 months.
Cellect Biotechnology's shares were split on a 1:4 basis on 23 September 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellect Biotechnology shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cellect Biotechnology shares which in turn could have impacted Cellect Biotechnology's share price.
Over the last 12 months, Cellect Biotechnology's shares have ranged in value from as little as $9.83 up to $35.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellect Biotechnology's is 1.8767. This would suggest that Cellect Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc. , in a reverse merger transaction. Cellect Biotechnology Ltd. , a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.